stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Net income
Haemonetics Corporation's net income for fiscal 2026 was $97.3M, down 42.0% from $167.7M in fiscal 2025. Over the twelve months to 30 September 2026 it was $103.9M. Over the past ten years it has ranged from −$55.6M (fiscal 2016) to $167.7M (fiscal 2025); the current reading is higher than 75% of that period. Haemonetics Corporation ranks 20th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | $97.3M | (41.97%) |
| FY2025 | $167.7M | 42.64% |
| FY2024 | $117.6M | 1.87% |
| FY2023 | $115.4M | 166.05% |
| FY2022 | $43.4M | (45.42%) |
| FY2021 | $79.5M | 3.85% |
| FY2020 | $76.5M | 39.09% |
| FY2019 | $55.0M | 20.73% |
| FY2018 | $45.6M | — |
| FY2017 | −$26.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $46.3M | 40.28% |
| Jun 2026 | $33.0M | — |
| Mar 2026 | −$20.1M | — |
| Dec 2025 | $44.7M | 15.66% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| LIVN LivaNova PLC compare | $196.1M |
| HAE Haemonetics Corporation | $103.9M |
| ITGR Integer Holdings Corporation compare | $103.7M |
| AXGN AxoGen, Inc. compare | −$31.9M |
| IRTC iRhythm Holdings, Inc. compare | −$38.6M |
| TXG 10x Genomics compare | −$75.1M |
| BRKR Bruker Corporation compare | −$115.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on HAE
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement